Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : National Institute on Aging
Deal Size : $3.0 million
Deal Type : Funding
Neurodon Awarded Nearly $3 Million from NIH to Advance its Drug for Alzheimer's Disease
Details : The funding will be used for continued development and Investigational New Drug (IND)-enabling studies to support clinical translation of the company's small molecule activators of the SERCA enzyme for Alzheimer's disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : National Institute on Aging
Deal Size : $3.0 million
Deal Type : Funding
Lead Product(s) : NDC-0009
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Orally-available NDC-0009 is one of several first-in-class curative molecules Neurodon is developing for multiple diseases by targeting specific cellular stress pathways.
Brand Name : NDC-0009
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2021
Lead Product(s) : NDC-0009
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?